Nevada Cancer Institute Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Summerlin NV United States (2002)

Organization Overview

First Clinical Trial
2006
NCT00281125
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Nevada Cancer Institute-Summerlin Campus

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 1)

Mesothelioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 10